Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
Purpose Since the introduction of PSMA PET/CT with 68 Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retros...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2018-11, Vol.45 (12), p.2045-2054 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2054 |
|---|---|
| container_issue | 12 |
| container_start_page | 2045 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 45 |
| creator | Afshar-Oromieh, Ali Debus, Nils Uhrig, Monika Hope, Thomas A. Evans, Michael J. Holland-Letz, Tim Giesel, Frederik L. Kopka, Klaus Hadaschik, Boris Kratochwil, Clemens Haberkorn, Uwe |
| description | Purpose
Since the introduction of PSMA PET/CT with
68
Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further analyse the influence of long-term ADT on PSMA PET/CT findings.
Methods
A retrospective analysis was performed of all 1,704 patients who underwent a
68
Ga-PSMA-11 PET/CT scan at our institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADT with a continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during ongoing ADT.
Results
Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42–369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71% and increased in 12.9% of the PC lesions. Of all lesions, 33.3% were still visible in six patients with a complete PSA response (≤0.1 ng/ml).
Conclusion
Continuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before starting ADT. |
| doi_str_mv | 10.1007/s00259-018-4079-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6182397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2066483771</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-e38df1c76e20b52d71901339e3a15293cf59c487887495c99764ed05c48f0ed63</originalsourceid><addsrcrecordid>eNp1kV1rFDEUhoMotlZ_gDcS8MabsfmYmSQ3QlmqLbRYcL0OaebMbMpMMibZLS3-eLPdulXBqxxynvOejxeht5R8pISI40QIa1RFqKxqIlR1_wwd0paqShCpnu9jQQ7Qq5RuSAGZVC_RAVNKEsnZIfp5Ps3GZhx6PAY_VBnihI3vYhjA4w7m6DYmu-BxXkE08x0u4dW3yxM8uqFw-Op0ebxYYufxXDjwOeFbl1fYmpTjQ2WVwCeX3QbwHEPKJkPJegvxNXrRmzHBm8f3CH3_fLpcnFUXX7-cL04uKlsLkivgsuupFS0wct2wTlBFKOcKuKENU9z2jbK1FFKKWjVWKdHW0JGm_PUEupYfoU873Xl9PUFny5TRjLrsNpl4p4Nx-u-Mdys9hI1uy8G4EkXgw6NADD_WkLKeXLIwjsZDWCfNSNvWkgtBC_r-H_QmrKMv622phgpaM1YouqNsuUiK0O-HoURvvdU7b3WxTG-91fel5t2fW-wrfptZALYDUkn5AeJT6_-r_gK6g7Ei</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2065171422</pqid></control><display><type>article</type><title>Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Afshar-Oromieh, Ali ; Debus, Nils ; Uhrig, Monika ; Hope, Thomas A. ; Evans, Michael J. ; Holland-Letz, Tim ; Giesel, Frederik L. ; Kopka, Klaus ; Hadaschik, Boris ; Kratochwil, Clemens ; Haberkorn, Uwe</creator><creatorcontrib>Afshar-Oromieh, Ali ; Debus, Nils ; Uhrig, Monika ; Hope, Thomas A. ; Evans, Michael J. ; Holland-Letz, Tim ; Giesel, Frederik L. ; Kopka, Klaus ; Hadaschik, Boris ; Kratochwil, Clemens ; Haberkorn, Uwe</creatorcontrib><description>Purpose
Since the introduction of PSMA PET/CT with
68
Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further analyse the influence of long-term ADT on PSMA PET/CT findings.
Methods
A retrospective analysis was performed of all 1,704 patients who underwent a
68
Ga-PSMA-11 PET/CT scan at our institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADT with a continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during ongoing ADT.
Results
Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42–369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71% and increased in 12.9% of the PC lesions. Of all lesions, 33.3% were still visible in six patients with a complete PSA response (≤0.1 ng/ml).
Conclusion
Continuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before starting ADT.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-018-4079-z</identifier><identifier>PMID: 29980832</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Androgens ; Androgens - metabolism ; Cardiology ; Castration ; Computed tomography ; Deprivation ; Edetic Acid - analogs & derivatives ; Humans ; Imaging ; Lesions ; Ligands ; Male ; Medical imaging ; Medicine ; Medicine & Public Health ; Middle Aged ; Nuclear Medicine ; Oligopeptides ; Oncology ; Original ; Original Article ; Orthopedics ; Patients ; Pheochromocytoma cells ; Positron emission ; Positron Emission Tomography Computed Tomography ; Prostate cancer ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - surgery ; Radiology ; Retrospective Studies ; Therapy ; Time Factors ; Tomography</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2018-11, Vol.45 (12), p.2045-2054</ispartof><rights>The Author(s) 2018</rights><rights>European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, (2018). All Rights Reserved. © 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-e38df1c76e20b52d71901339e3a15293cf59c487887495c99764ed05c48f0ed63</citedby><cites>FETCH-LOGICAL-c470t-e38df1c76e20b52d71901339e3a15293cf59c487887495c99764ed05c48f0ed63</cites><orcidid>0000-0002-4492-4243</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-018-4079-z$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-018-4079-z$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29980832$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Afshar-Oromieh, Ali</creatorcontrib><creatorcontrib>Debus, Nils</creatorcontrib><creatorcontrib>Uhrig, Monika</creatorcontrib><creatorcontrib>Hope, Thomas A.</creatorcontrib><creatorcontrib>Evans, Michael J.</creatorcontrib><creatorcontrib>Holland-Letz, Tim</creatorcontrib><creatorcontrib>Giesel, Frederik L.</creatorcontrib><creatorcontrib>Kopka, Klaus</creatorcontrib><creatorcontrib>Hadaschik, Boris</creatorcontrib><creatorcontrib>Kratochwil, Clemens</creatorcontrib><creatorcontrib>Haberkorn, Uwe</creatorcontrib><title>Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Since the introduction of PSMA PET/CT with
68
Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further analyse the influence of long-term ADT on PSMA PET/CT findings.
Methods
A retrospective analysis was performed of all 1,704 patients who underwent a
68
Ga-PSMA-11 PET/CT scan at our institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADT with a continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during ongoing ADT.
Results
Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42–369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71% and increased in 12.9% of the PC lesions. Of all lesions, 33.3% were still visible in six patients with a complete PSA response (≤0.1 ng/ml).
Conclusion
Continuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before starting ADT.</description><subject>Aged</subject><subject>Androgens</subject><subject>Androgens - metabolism</subject><subject>Cardiology</subject><subject>Castration</subject><subject>Computed tomography</subject><subject>Deprivation</subject><subject>Edetic Acid - analogs & derivatives</subject><subject>Humans</subject><subject>Imaging</subject><subject>Lesions</subject><subject>Ligands</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nuclear Medicine</subject><subject>Oligopeptides</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Pheochromocytoma cells</subject><subject>Positron emission</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Radiology</subject><subject>Retrospective Studies</subject><subject>Therapy</subject><subject>Time Factors</subject><subject>Tomography</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kV1rFDEUhoMotlZ_gDcS8MabsfmYmSQ3QlmqLbRYcL0OaebMbMpMMibZLS3-eLPdulXBqxxynvOejxeht5R8pISI40QIa1RFqKxqIlR1_wwd0paqShCpnu9jQQ7Qq5RuSAGZVC_RAVNKEsnZIfp5Ps3GZhx6PAY_VBnihI3vYhjA4w7m6DYmu-BxXkE08x0u4dW3yxM8uqFw-Op0ebxYYufxXDjwOeFbl1fYmpTjQ2WVwCeX3QbwHEPKJkPJegvxNXrRmzHBm8f3CH3_fLpcnFUXX7-cL04uKlsLkivgsuupFS0wct2wTlBFKOcKuKENU9z2jbK1FFKKWjVWKdHW0JGm_PUEupYfoU873Xl9PUFny5TRjLrsNpl4p4Nx-u-Mdys9hI1uy8G4EkXgw6NADD_WkLKeXLIwjsZDWCfNSNvWkgtBC_r-H_QmrKMv622phgpaM1YouqNsuUiK0O-HoURvvdU7b3WxTG-91fel5t2fW-wrfptZALYDUkn5AeJT6_-r_gK6g7Ei</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Afshar-Oromieh, Ali</creator><creator>Debus, Nils</creator><creator>Uhrig, Monika</creator><creator>Hope, Thomas A.</creator><creator>Evans, Michael J.</creator><creator>Holland-Letz, Tim</creator><creator>Giesel, Frederik L.</creator><creator>Kopka, Klaus</creator><creator>Hadaschik, Boris</creator><creator>Kratochwil, Clemens</creator><creator>Haberkorn, Uwe</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4492-4243</orcidid></search><sort><creationdate>20181101</creationdate><title>Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer</title><author>Afshar-Oromieh, Ali ; Debus, Nils ; Uhrig, Monika ; Hope, Thomas A. ; Evans, Michael J. ; Holland-Letz, Tim ; Giesel, Frederik L. ; Kopka, Klaus ; Hadaschik, Boris ; Kratochwil, Clemens ; Haberkorn, Uwe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-e38df1c76e20b52d71901339e3a15293cf59c487887495c99764ed05c48f0ed63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Androgens</topic><topic>Androgens - metabolism</topic><topic>Cardiology</topic><topic>Castration</topic><topic>Computed tomography</topic><topic>Deprivation</topic><topic>Edetic Acid - analogs & derivatives</topic><topic>Humans</topic><topic>Imaging</topic><topic>Lesions</topic><topic>Ligands</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nuclear Medicine</topic><topic>Oligopeptides</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Pheochromocytoma cells</topic><topic>Positron emission</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Radiology</topic><topic>Retrospective Studies</topic><topic>Therapy</topic><topic>Time Factors</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Afshar-Oromieh, Ali</creatorcontrib><creatorcontrib>Debus, Nils</creatorcontrib><creatorcontrib>Uhrig, Monika</creatorcontrib><creatorcontrib>Hope, Thomas A.</creatorcontrib><creatorcontrib>Evans, Michael J.</creatorcontrib><creatorcontrib>Holland-Letz, Tim</creatorcontrib><creatorcontrib>Giesel, Frederik L.</creatorcontrib><creatorcontrib>Kopka, Klaus</creatorcontrib><creatorcontrib>Hadaschik, Boris</creatorcontrib><creatorcontrib>Kratochwil, Clemens</creatorcontrib><creatorcontrib>Haberkorn, Uwe</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Afshar-Oromieh, Ali</au><au>Debus, Nils</au><au>Uhrig, Monika</au><au>Hope, Thomas A.</au><au>Evans, Michael J.</au><au>Holland-Letz, Tim</au><au>Giesel, Frederik L.</au><au>Kopka, Klaus</au><au>Hadaschik, Boris</au><au>Kratochwil, Clemens</au><au>Haberkorn, Uwe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>45</volume><issue>12</issue><spage>2045</spage><epage>2054</epage><pages>2045-2054</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
Since the introduction of PSMA PET/CT with
68
Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further analyse the influence of long-term ADT on PSMA PET/CT findings.
Methods
A retrospective analysis was performed of all 1,704 patients who underwent a
68
Ga-PSMA-11 PET/CT scan at our institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADT with a continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during ongoing ADT.
Results
Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42–369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71% and increased in 12.9% of the PC lesions. Of all lesions, 33.3% were still visible in six patients with a complete PSA response (≤0.1 ng/ml).
Conclusion
Continuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before starting ADT.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29980832</pmid><doi>10.1007/s00259-018-4079-z</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4492-4243</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2018-11, Vol.45 (12), p.2045-2054 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6182397 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Androgens Androgens - metabolism Cardiology Castration Computed tomography Deprivation Edetic Acid - analogs & derivatives Humans Imaging Lesions Ligands Male Medical imaging Medicine Medicine & Public Health Middle Aged Nuclear Medicine Oligopeptides Oncology Original Original Article Orthopedics Patients Pheochromocytoma cells Positron emission Positron Emission Tomography Computed Tomography Prostate cancer Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - drug therapy Prostatic Neoplasms - metabolism Prostatic Neoplasms - surgery Radiology Retrospective Studies Therapy Time Factors Tomography |
| title | Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A19%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20long-term%20androgen%20deprivation%20therapy%20on%20PSMA%20ligand%20PET/CT%20in%20patients%20with%20castration-sensitive%20prostate%20cancer&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Afshar-Oromieh,%20Ali&rft.date=2018-11-01&rft.volume=45&rft.issue=12&rft.spage=2045&rft.epage=2054&rft.pages=2045-2054&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-018-4079-z&rft_dat=%3Cproquest_pubme%3E2066483771%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2065171422&rft_id=info:pmid/29980832&rfr_iscdi=true |